Cited by 2,961Protein Degradation and InhibitorsChromatin Remodeling and CancerGenomics and Chromatin Dynamics

The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

Open access

Lovén, Jakob, Hoke, Heather A., Lin, Charles Y., Lau, Ashley, Orlando, David A., Vakoc, Christopher R., Bradner, James E., Lee, Tong Ihn, Young, Richard A.·2013·Cell

DOI 10.1016/j.cell.2013.03.036PMC PMC3760967

Open this paper in CoChat — free account Open PDF

Abstract

Chromatin regulators have become attractive targets for cancer therapy, but it is unclear why inhibition of these ubiquitous regulators should have gene-specific effects in tumor cells. Here, we investigate how inhibition of the widely expressed transcriptional coactivator BRD4 leads to selective inhibition of the MYC oncogene in multiple myeloma (MM). BRD4 and Mediator were found to co-occupy thousands of enhancers associated with active genes. They also co-occupied a small set of exceptionally large super-enhancers associated with genes that feature prominently in MM biology, including the MYC oncogene. Treatment of MM tumor cells with the BET-bromodomain inhibitor JQ1 led to preferential loss of BRD4 at super-enhancers and consequent transcription elongation defects that preferentially impacted genes with super-enhancers, including MYC. Super-enhancers were found at key oncogenic drivers in many other tumor cells. These observations have implications for the discovery of cancer therapeutics directed at components of super-enhancers in diverse tumor types.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2013.03.036

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Topological domains in mammalian genomes identified by analysis of chromatin interactions
Dixon, J. R., Selvaraj, S., Yue, F., Kim, A., Li, Y., Shen, Y., Hu, M., Liu, J. S., & Ren, B. (2012) · Nature · doi:10.1038/nature11082 · Cited by 6,829
NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins
Pruitt, K. D., Tatusova, T. A., & Maglott, D. R. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl842 · Cited by 4,441
Histone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
Self-citation
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Self-citation
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Self-citation
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Epigenetics in Cancer
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,767
Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclassesPreprint
Cabili, M. N., Trapnell, C., Goff, L. A., Koziol, M. J., Tazón‐Vega, B., Regev, A., & Rinn, J. L. (2011) · Genes & Development · doi:10.1101/gad.17446611 · Cited by 3,551

Flagged first, then by citations

Show all 86 references

Sorted by citations

Items 401–500 of 1,008

Interplay and cooperation between SREBF1 and master transcription factors regulate lipid metabolism and tumor-promoting pathways in squamous cancer
Li, L.-Y., Yang, Q., Jiang, Y.-Y., Yang, W., Jiang, Y. Y., Li, X., Hazawa, M., Zhou, B. O., Huang, G.-W., Xu, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24656-x · Cited by 125
BET inhibition disrupts transcription but retains enhancer-promoter contact
Crump, N. T., Ballabio, E., Godfrey, L., Thorne, R., Repapi, E., Kerry, J., Tapia, M., Hua, P., Lagerholm, C., Filippakopoulos, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20400-z · Cited by 123
Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression
Li, G.-Q., Guo, W.-Z., Zhang, Y., Seng, J.-J., Zhang, H., Ma, X.-X., Zhang, G., Li, J., Yan, B., Tang, H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6275 · Cited by 121
BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells
Baker, E. K., Taylor, S., Gupte, A., Sharp, P. P., Walia, M., Walsh, N. C., Zannettino, A. C. W., Chalk, A. M., Burns, C. J., & Walkley, C. R. (2015) · Scientific Reports · doi:10.1038/srep10120 · Cited by 123
Excess Translation of Epigenetic Regulators Contributes to Fragile X Syndrome and Is Alleviated by Brd4 Inhibition
Korb, E., Herre, M., Zucker-Scharff, I., Gresack, J. E., Allis, C. D., & Darnell, R. B. (2017) · Cell · doi:10.1016/j.cell.2017.07.033 · Cited by 122
Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain
Law, R. P., Atkinson, S. J., Bamborough, P., Chung, C., Demont, E. H., Gordon, L. J., Lindon, M. J., Prinjha, R. K., Watson, A. J. B., & Hirst, D. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01666 · Cited by 121
HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells
Caslini, C., Hong, S., Ban, Y. J., Chen, X. S., & Ince, T. A. (2019) · Oncogene · doi:10.1038/s41388-019-0897-0 · Cited by 121
A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer
Chen, H., & Liang, H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.020 · Cited by 125
The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response
Hussong, M., Börno, S. T., Kerick, M., Wunderlich, A., Franz, A. M., Sültmann, H., Timmermann, B., Lehrach, H., Hirsch‐Kauffmann, M., & Schweiger, M. R. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.157 · Cited by 119
The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects
Shahbazi, J., Liu, P. Y., Atmadibrata, B., Bradner, J. E., Marshall, G. M., Lock, R. B., & Liu, T. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1666 · Cited by 122
Self-citation
Bromodomain 4: a cellular Swiss army knife
Devaiah, B. N., Gégonne, A., & Singer, D. S. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.2ri0616-250r · Cited by 124
Epigenetics in Cardiac Fibrosis
Felisbino, M. B., & McKinsey, T. A. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.05.003 · Cited by 124
Emerging epigenetic-modulating therapies in lymphoma
Sermer, D. J., Pasqualucci, L., Wendel, H., Melnick, A. M., & Younes, A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0190-8 · Cited by 125
Identification and functional characterization of transcriptional activators in human cells
Alerasool, N., Leng, H., Lin, Z.-Y., Gingras, A.-C., & Taipale, M. (2022) · Molecular Cell · doi:10.1016/j.molcel.2021.12.008 · Cited by 120
Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome
Cohen, A. J., Saiakhova, A., Corradin, O., Luppino, J. M., Lovrenert, K., Bartels, C. F., Morrow, J. J., Mack, S. C., Dhillon, G. K., Beard, L., et al. (2017) · Nature Communications · doi:10.1038/ncomms14400 · Cited by 118
Self-citation
Long-Range Enhancer Interactions Are Prevalent in Mouse Embryonic Stem Cells and Are Reorganized upon Pluripotent State Transition
Novo, C. L., Javierre, B.-M., Cairns, J., Segonds-Pichon, A., Wingett, S. W., Freire-Pritchett, P., Furlan-Magaril, M., Schoenfelder, S., Fraser, P., & Rugg-Gunn, P. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.040 · Cited by 119
HACER: an atlas of human active enhancers to interpret regulatory variants
Wang, J., Dai, X., Berry, L. D., Cogan, J. D., Liu, Q., & Shyr, Y. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky864 · Cited by 110
The transcription factor ERG regulates super-enhancers associated with an endothelial-specific gene expression program
Kalna, V., Yang, Y., Peghaire, C. R., Frudd, K., Hannah, R., Shah, A. V., Osuna Almagro, L., Boyle, J. J., Göttgens, B., Ferrer, J., et al. (2019) · Circulation Research · doi:10.1161/circresaha.118.313788 · Cited by 119
Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer
Wang, W., Tang, Y., Xiao, Q., Lee, W. C., Cheng, B., Niu, Z., Oguz, G., Feng, M., Lee, P. L., Li, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24687-4 · Cited by 119
Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma
Gandhi, U. H., Senapedis, W. T., Baloglu, E., Unger, T. J., Chari, A., Vogl, D. T., & Cornell, R. F. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.03.003 · Cited by 118
Nested epistasis enhancer networks for robust genome regulation
Lin, X., Liu, Y., Liu, S., Zhu, X., Wu, L., Zhu, Y., Zhao, D., Xu, X., Chemparathy, A., Wang, H., et al. (2022) · Science · doi:10.1126/science.abk3512 · Cited by 112
Advances and perspectives of PARP inhibitors
Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K., & Luo, S. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0154-9 · Cited by 117
Evidence for additive and synergistic action of mammalian enhancers during cell fate determination
Choi, J., Lysakovskaia, K., Stik, G., Demel, C., Söding, J., Tian, T. V., Graf, T., & Cramer, P. (2021) · eLife · doi:10.7554/elife.65381 · Cited by 117
Genome-wide profiling in colorectal cancer identifies PHF19 and TBC1D16 as oncogenic super enhancers
Li, Q., Lin, X., Yu, Y., Chen, L., Hu, Q., Chen, M., Cao, N., Zhao, C., Wang, C.-Y., Huang, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26600-5 · Cited by 117
Bromodomain Histone Readers and Cancer
Jain, A. K., & Barton, M. C. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.11.020 · Cited by 116
PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer
Spangle, J. M., Dreijerink, K. M. A., Groner, A. C., Cheng, H.-L. M., Ohlson, C. E., Reyes, J. M., Lin, C. Y., Bradner, J. E., Zhao, J. J., Roberts, T. M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.046 · Cited by 118
Self-citation
Hypertranscription in Development, Stem Cells, and Regeneration
Percharde, M., Bulut-Karslıoğlu, A., & Ramalho‐Santos, M. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.11.010 · Cited by 122
Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function
Gui, B., Gui, F., Takai, T., Feng, C., Bai, X., Fazli, L., Dong, X., Liu, S., Zhang, X., Zhang, W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908547116 · Cited by 114
Transcriptional Regulation by (Super)Enhancers: From Discovery to Mechanisms
Grosveld, F., van Staalduinen, J., & Stadhouders, R. (2021) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-122220-093818 · Cited by 115
Enhanced Identification of Transcriptional Enhancers Provides Mechanistic Insights into Diseases
Murakawa, Y., Yoshihara, M., Kawaji, H., Nishikawa, M., Zayed, H., Suzuki, H., & Hayashizaki, Y. (2016) · Trends in Genetics · doi:10.1016/j.tig.2015.11.004 · Cited by 112
Functional interdependence of BRD4 and DOT1L in MLL leukemia
Gilan, O., Lam, E. Y. N., Becher, I., Lugo, D., Cannizzaro, E., Joberty, G., Ward, A., Wiese, M., Fong, C. Y., Ftouni, S., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3249 · Cited by 118
Epigenetic regulation in cancer
Gu, M., Ren, B., Fang, Y., Ren, J., Liu, X., Wang, X., Zhou, F., Xiao, R., Luo, X., You, L., et al. (2024) · MedComm · doi:10.1002/mco2.495 · Cited by 126
p300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-Deficient Prostate Tumorigenesis
Zhong, J., Ding, L., Bohrer, L. R., Pan, Y., Liu, P., Zhang, J., Sebo, T. J., Karnes, R. J., Tindall, D. J., van Deursen, J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2485 · Cited by 114
Non-coding RNAs, epigenetics, and cancer: tying it all together
Ferreira, H. J., & Esteller, M. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9715-8 · Cited by 116
Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors
Bechter, O. E., & Schöffski, P. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107479 · Cited by 117
Super-enhancers: critical roles and therapeutic targets in hematologic malignancies
Jia, Y., Chng, W. J., & Zhou, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0757-y · Cited by 120
Enhancer deregulation in cancer and other diseases
Herz, H. (2016) · BioEssays · doi:10.1002/bies.201600106 · Cited by 110
EnhancerPred: a predictor for discovering enhancers based on the combination and selection of multiple features
Jia, C., & He, W. (2016) · Scientific Reports · doi:10.1038/srep38741 · Cited by 110
The Functions of BET Proteins in Gene Transcription of Biology and Diseases
Cheung, K. L., Kim, C., & Zhou, M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.728777 · Cited by 115
MYC and Transcription ElongationPreprint
Rahl, P. B., & Young, R. A. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a020990 · Cited by 119
Self-citation
Chromatin and epigenetic features of long-range gene regulation
Harmston, N., & Lenhard, B. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt499 · Cited by 113
Comprehensive analysis of promoter-proximal RNA polymerase II pausing across mammalian cell types
Day, D. S., Zhang, B., Stevens, S. M., Ferrari, F., Larschan, E., Park, P. J., & Pu, W. T. (2016) · Genome biology · doi:10.1186/s13059-016-0984-2 · Cited by 115
Enhancer RNAs in cancer: regulation, mechanisms and therapeutic potential
Lee, J., Xiong, F., & Li, W. (2020) · RNA Biology · doi:10.1080/15476286.2020.1712895 · Cited by 108
Synergistic effect of JQ 1 and rapamycin for treatment of human osteosarcoma
Lee, D. H., Qi, J., Bradner, J. E., SAID, J. W., Doan, N., Forscher, C. A., Yang, H. H., & Koeffler, H. P. (2014) · International Journal of Cancer · doi:10.1002/ijc.29269 · Cited by 110
Self-citation
Targeting transcription factors
Yeh, J., Toniolo, P. A., & Frank, D. A. (2013) · Current Opinion in Oncology · doi:10.1097/01.cco.0000432528.88101.1a · Cited by 109
Novel biological insights in T-cell acute lymphoblastic leukemia
Durinck, K., Goossens, S., Peirs, S., Wallaert, A., Loocke, W. V., Matthijssens, F., Pieters, T., Milani, G., Lammens, T., Rondou, P., et al. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.017 · Cited by 111
Strategically targeting MYC in cancer
Posternak, V., & Cole, M. D. (2016) · F1000Research · doi:10.12688/f1000research.7879.1 · Cited by 108
Long non-coding RNAs: An emerging powerhouse in the battle between life and death of tumor cells
Xiong, X.-D., Ren, X., Cai, M., Yang, J. W., Liu, X., & Yang, J. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.04.001 · Cited by 109
Spatially clustered loci with multiple enhancers are frequent targets of HIV-1 integration
Lucic, B., Chen, H., Kuzman, M., Zorita, E. V., Wegner, J., Minneker, V., Wang, W., Fronza, R., Laufs, S., Schmidt, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12046-3 · Cited by 111
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity
Watt, A. C. S., Cejas, P., DeCristo, M. J., Metzger, O., Lam, E. Y. N., Qiu, X., BrinJones, H., Kesten, N., Coulson, R. S., Font‐Tello, A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00135-y · Cited by 112
HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies
Slaughter, M. J., Shanle, E. K., Khan, A. A., Chua, K. F., Hong, T., Boxer, L. D., Allis, C. D., Josefowicz, S. Z., Garcia, B. A., Rothbart, S. B., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108638 · Cited by 107
PRRX1 is a master transcription factor of stromal fibroblasts for myofibroblastic lineage progression
Lee, K.-W., Yeo, S.-Y., Gong, J.-R., Koo, O.-J., Sohn, I., Lee, W. Y., Kim, H. C., Yun, S. H., Cho, Y. B., Choi, M.-A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30484-4 · Cited by 103
Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
Kulikowski, E., Rakai, B. D., & Wong, N. C. W. (2020) · Medicinal Research Reviews · doi:10.1002/med.21730 · Cited by 109
Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma
Li, Z., Liu, H., He, J., Wang, Z., Yin, Z., You, G., Wang, Z., Davis, R. E., Lin, P., Bergsagel, P. L., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.12.011 · Cited by 110
FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program
Zhang, M., Hoyle, R. G., Ma, Z., Sun, B., Cai, W., Cai, H., Xie, N., Zhang, Y., Hou, J., Liu, X., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.03.024 · Cited by 108
Now open: Evolving insights to the roles of lysine acetylation in chromatin organization and function
Chen, Y.-J. C., Koutelou, E., & Dent, S. (2022) · Molecular Cell · doi:10.1016/j.molcel.2021.12.004 · Cited by 110
Molecular Pathways: Targeting MYC-induced Metabolic Reprogramming and Oncogenic Stress in Cancer
Li, B., & Simon, M. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3629 · Cited by 108
RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells
van Bragt, M. P. A., Hu, X., Xie, Y., & Li, Z. (2014) · eLife · doi:10.7554/elife.03881 · Cited by 105
Discovery of Chemical Inhibitors of Human Bromodomains
Zhang, G., Smith, S. G., & Zhou, M. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00205 · Cited by 108
Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma
Jiang, Y. Y., Jiang, Y.-Y., Mayakonda, A., Huang, M., Ding, L., Han, L., Yu, F., Lu, Y., Loh, T. K. S., Chow, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1143 · Cited by 105
Clinical advances in targeting epigenetics for cancer therapy
Feng, S., & Carvalho, D. D. D. (2021) · FEBS Journal · doi:10.1111/febs.15750 · Cited by 109
Design Principles of Concentration-Dependent Transcriptome Deviations in Drug-Exposed Differentiating Stem Cells
Waldmann, T., Rempel, E., Balmer, N. V., König, A., Kolde, R., Gaspar, J. A., Henry, M., Hescheler, J., Sachinidis, A., Rahnenführer, J., et al. (2014) · Chemical Research in Toxicology · doi:10.1021/tx400402j · Cited by 106
Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets
Qian, H., Zhu, M., Tan, X., Zhang, Y., Liu, X., & Yang, L. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01775-6 · Cited by 106
EZH2 in normal hematopoiesis and hematological malignancies
Herviou, L., Cavalli, G., Cartron, G., Klein, B., & Moreaux, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6198 · Cited by 113
Enhancers, enhancers – from their discovery to today’s universe of transcription enhancers
Schaffner, W. (2015) · Biological Chemistry · doi:10.1515/hsz-2014-0303 · Cited by 105
Many Inflammatory Bowel Disease Risk Loci Include Regions That Regulate Gene Expression in Immune Cells and the Intestinal Epithelium
Mokrý, M., Middendorp, S., Wiegerinck, C. L., Witte, M., Teunissen, H., Meddens, C., Cuppen, E. P. J. G., Clevers, H. C., & Nieuwenhuis, E. E. S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.12.003 · Cited by 107
BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer
Wu, X., Liu, D., Tao, D., Xiang, W., Xiao, X., Wang, M., Wang, L., Luo, G., Li, Y., Zeng, F., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0750 · Cited by 111
C/EBPα creates elite cells for iPSC reprogramming by upregulating Klf4 and increasing the levels of Lsd1 and Brd4
Stefano, B. D., Collombet, S., Jakobsen, J. S., Wierer, M., Sardina, J. L., Lackner, A., Stadhouders, R., Segura-Morales, C., Francesconi, M., Limone, F., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3326 · Cited by 106
Regulation of angiotensin II actions by enhancers and super-enhancers in vascular smooth muscle cells
Das, S., Senapati, P., Chen, Z., Reddy, M. A., Ganguly, R., Lanting, L. L., Mandi, V., Bansal, A., Leung, A., Zhang, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01629-7 · Cited by 105
MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis
Brescia, P., Schneider, C., Holmes, A. B., Shen, Q. “., Hussein, S., Pasqualucci, L., Basso, K., & Dalla‐Favera, R. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.006 · Cited by 114
Therapeutic targeting of transcriptional cyclin-dependent kinases
Galbraith, M. D., Bender, H., & Espinosa, J. M. (2018) · Transcription · doi:10.1080/21541264.2018.1539615 · Cited by 104
Mutant NPM1 Hijacks Transcriptional Hubs to Maintain Pathogenic Gene Programs in Acute Myeloid Leukemia
Wang, X. Q. D., Fan, D., Han, Q., Liu, Y., Miao, H. Z., Wang, X., Li, Q., Chen, D., Gore, H., Himadewi, P., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0424 · Cited by 106
SEanalysis 2.0: a comprehensive super-enhancer regulatory network analysis tool for human and mouse
Qian, F., Zhou, L., Li, Y., Yu, Z., Li, L., Wang, Y., Xu, M., Wang, Q., & Li, C. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad408 · Cited by 105
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib
Sun, B., Shah, B., Fiskus, W. C., Qi, J., Rajapakshe, K., Coarfa, C., Li, L., Devaraj, S. G. T., Sharma, S., Zhang, L., et al. (2015) · Blood · doi:10.1182/blood-2015-04-639542 · Cited by 110
Self-citation
Inhibition of Super-Enhancer Activity in Autoinflammatory Site-Derived T Cells Reduces Disease-Associated Gene Expression
Peeters, J. G. C., Vervoort, S. J., Tan, S., Mijnheer, G., de Roock, S., Vastert, S. J., Nieuwenhuis, E. E. S., van Wijk, F., Prakken, B. J., Creyghton, M. P., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.046 · Cited by 100
SEA: a super-enhancer archive
Wei, Y., Zhang, S., Shang, S., Zhang, B., Li, S., Wang, X., Wang, F., Su, J., Wu, Q., Liu, H., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1243 · Cited by 104
Chromodomain Antagonists That Target the Polycomb-Group Methyllysine Reader Protein Chromobox Homolog 7 (CBX7)
Simhadri, C., Daze, K. D., Douglas, S. F., Quon, T. T. H., Dev, A., Gignac, M. C., Peng, F., Heller, M., Boulanger, M. J., Wulff, J. E., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401487x · Cited by 103
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer
Liu, J., Duan, Z., Guo, W., Zeng, L., Wu, Y., Chen, Y., Tai, F., Wang, Y., Lin, Y., Zhang, Q., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07258-y · Cited by 103
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
Miller, A. L., Fehling, S. C., Garcia, P. L., Gamblin, T. L., van Waardenburg, R. C. A. M., Yang, E. S.-H., Bradner, J. E., & Yoon, K. J. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.05.035 · Cited by 103
Self-citation
Papillomavirus Genomes Associate with BRD4 to Replicate at Fragile Sites in the Host Genome
Jang, M. K., Shen, K., & McBride, A. A. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004117 · Cited by 104
Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming
Xiong, L., Wu, F., Wu, Q., Xu, L., Cheung, O. K.-W., Kang, W., Mok, M. T. S., Szeto, L. L. M., Lun, C.-Y., Lung, R. W. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08245-z · Cited by 106
Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression
Zhang, F., Biswas, M., Massah, S., Lee, J., Lingadahalli, S., Wong, S. T. S., Wells, C. A., Foo, J., Khan, N., Morin, H., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac1158 · Cited by 108
Cancer resistance and metastasis are maintained through oxidative phosphorylation
Uslu, C., Kapan, E., & Lyakhovich, A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216705 · Cited by 112
Functions of BET proteins in erythroid gene expression
Stonestrom, A. J., Hsu, S. C., Jahn, K. S., Huang, P., Keller, C. A., Giardine, B. M., Kadauke, S., Campbell, A. E., Evans, P., Hardison, R. C., et al. (2015) · Blood · doi:10.1182/blood-2014-10-607309 · Cited by 107
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
Moros, A., Rodríguez, V., Saborit-Villarroya, I., Montraveta, A., Balsas, P., Sandy, P., Martı́nez, A., Wiestner, A. U., Normant, E., Campo, E., et al. (2014) · Leukemia · doi:10.1038/leu.2014.106 · Cited by 104
The Super-Enhancer-Derived alncRNA-EC7/Bloodlinc Potentiates Red Blood Cell Development in trans
Alvarez‐Dominguez, J. R., Knoll, M., Gromatzky, A. A., & Lodish, H. F. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.082 · Cited by 103
PEDLA: predicting enhancers with a deep learning-based algorithmic framework
Liu, F., Li, H., Ren, C., Bo, X., & Shu, W. (2016) · Scientific Reports · doi:10.1038/srep28517 · Cited by 101
Targeting DNA repair in cancer: current state and novel approaches
Klinakis, A., Karagiannis, D., & Rampias, T. N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03299-8 · Cited by 108
Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities
Tanaka, Y., Chiwaki, F., Kojima, S., Kawazu, M., Komatsu, M., Ueno, T., Inoue, S., Sekine, S., Matsusaki, K., Matsushita, H., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00240-6 · Cited by 107
BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer
Liu, B., Liu, X., Han, L., Chen, X., Wu, X., Wu, J., Yan, D., Wang, Y., Liu, S., Shan, L., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2109133119 · Cited by 104
Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma
Kennedy, A. L., Vallurupalli, M., Chen, L., Crompton, B. D., Cowley, G. S., Vázquez, F., Weir, B. A., Tsherniak, A., Parasuraman, S., Kim, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4903 · Cited by 105
Neuronal identity genes regulated by super-enhancers are preferentially down-regulated in the striatum of Huntington's disease mice
Achour, M., Gras, S. L., Keime, C., Parmentier, F., Lejeune, F., Boutillier, A., Néri, C., Davidson, I., & Mérienne, K. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv099 · Cited by 99
Prognostic DNA Methylation Markers for Prostate Cancer
Strand, S. H., Orntoft, T. F., & Sørensen, K. D. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150916544 · Cited by 106
Targeting BET bromodomain proteins in solid tumors
Sahai, V., Redig, A. J., Collier, K. A., Eckerdt, F., & Munshi, H. G. (2016) · Oncotarget · doi:10.18632/oncotarget.9804 · Cited by 103
Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression
Jain, S. U., Khazaei, S., Marchione, D. M., Lundgren, S. M., Wang, X., Weinberg, D. N., Deshmukh, S., Juretic, N., Lü, C., Allis, C. D., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006076117 · Cited by 108
Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype
Wu, Y., Fletcher, M., Gu, Z., Wang, Q., Costa, B., Bertoni, A., Man, K.-H., Schlotter, M., Felsberg, J., Mangei, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20225-w · Cited by 101
Aberrant phase separation and cancer
Taniue, K., & Akimitsu, N. (2021) · FEBS Journal · doi:10.1111/febs.15765 · Cited by 101
Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence
Wu, Z., Zhou, J. R., Zhang, X., Zhang, Z., Xie, Y., Liu, J. B., Ho, Z. V., Panda, A., Qiu, X., Cejas, P., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00859-2 · Cited by 101
Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells
Korkut, A., Wang, W., Demir, E., Aksoy, B. A., Jing, X., Molinelli, E. J., Babur, Ö., Bemis, D. L., Sümer, S. O., Solit, D. B., et al. (2015) · eLife · doi:10.7554/elife.04640 · Cited by 99
Targeting Super-Enhancers for Disease Treatment and Diagnosis.
Shin, H. Y. (2018) · Europe PMC (PubMed Central) · doi:10.14348/molcells.2018.2297 · Cited by 101

Authors: Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A.
Affiliations: Whitehead Institute for Biomedical Research (US)
Dana-Farber Cancer Institute (US)
Cold Spring Harbor Laboratory (US)
Harvard University (US)
Corresponding author: Young, Richard A.
ORCID: Lin, Charles Y.
Orlando, David A.
Vakoc, Christopher R.
Bradner, James E.
Lee, Tong Ihn
Young, Richard A.
Venue: Cell
Publisher: Elsevier BV
Published: 2013-04
Volume: 153
Issue: 2
Pages: 320-334
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2013.03.036
PMC: PMC3760967
OpenAlex: W1523117612
Cited by: 2,961
References: 86
Citations by year: 2026: 140 · 2025: 214 · 2024: 261 · 2023: 254 · 2022: 271 · 2021: 327 · 2020: 263 · 2019: 248 · 2018: 218 · 2017: 205 · 2016: 184 · 2015: 175 · 2014: 143 · 2013: 53
FWCI: 83.08
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 375 d)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
Funders: National Institutes of Health (5p30ca045508-35)
National Human Genome Research Institute (HG002668, R01HG002668)
National Cancer Institute (CA146445, R01CA146445, P30-CA045508, CA45508, P30CA014051)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords: super-enhancers, BRD4, MYC oncogene, multiple myeloma, BET inhibitors, JQ1, Mediator complex, transcriptional coactivator, transcription elongation, chromatin regulators, cancer therapy, enhancer disruption
MeSH terms: Bromodomain Containing Proteins, Antineoplastic Agents, Azepines, Chromatin, Enhancer Elements, Genetic, Humans, Multiple Myeloma, Neoplasms, Nuclear Proteins, Transcription Factors, Transcription, Genetic, Triazoles, Gene Expression Regulation, Neoplastic, Cell Cycle Proteins, Cell Line, Tumor, Genome-Wide Association Study, Mediator Complex, Transcription Elongation, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks